Numinus Wellness Updates on Annual Filings Amid Management Cease Trade Order

VANCOUVER, BC, Jan. 1, 2025 /PRNewswire/ – Numinus Wellness Inc. NUMI NUMIF (“Numinus” or the “Company“) specializes in mental health care with a focus on innovative, evidence-based treatments. Today, the Company offered an important update regarding its management cease trade order (“MCTO“) related to its upcoming audited annual financial statements (the “Audited Financial Statements“), management discussion and analysis (the “MD&A“), and annual information form (the “AIF“) for the financial year ending August 31, 2024 (collectively, the “Annual Filings“).

Cessation of Trading for Executives

Following the Company’s announcement on December 3, 2024, the British Columbia Securities Commission (Commission) approved the MCTO on December 2, 2024. This order is part of National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“). Under this directive, the Company’s Chief Executive Officer and Chief Financial Officer must refrain from trading the Company’s securities until the Annual Filings are submitted and the MCTO is lifted. During this time, the Company will suspend all share buy-back activities and refrain from issuing or acquiring securities from any insiders or employees.

Shareholders Remain Unaffected

Importantly, the MCTO does not restrict shareholders from trading their securities. The Board of Directors and management are working diligently with the accounting team to finalize the Annual Filings as soon as possible. Delays in filing were due to unexpected challenges, but the Company expects to complete the Annual Filings by January 28, 2025.

Ongoing Compliance and Updates

A news release will announce when the Annual Filings are completed. Until then, Numinus will follow alternative information guidelines under NP 12-203, including issuing bi-weekly default status reports via news releases to be filed on SEDAR+.

Since the prior announcement, the Company confirms that it has adhered to the alternative information guidelines. There have been no defaults under NP 12-203, no insolvency proceedings involving the Company, and no undisclosed material information regarding the Company.

About Numinus

Numinus Wellness Inc. NUMI is dedicated to healing through innovative mental health care and safe, evidence-based psychedelic-assisted therapies. Numinus integrates psychedelic research with clinical practice, focusing on treating symptoms of depression, anxiety, trauma, pain, and substance use. The Company aims to establish a healthier society by leading the adoption of these therapies. For more information, visit www.numinus.com or follow us on LinkedIn, Facebook, and Instagram.

Forward Looking Statements

The statements in this release that indicate anticipated future events are known as forward-looking statements. These statements often use terms like “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, and expressions indicating potential occurrences. Specifically, this release includes forward-looking statements about the expected completion of Annual Filings by January 28, 2025 and adherence to the MCTO and NP 12-203. Risks and uncertainties could significantly alter actual results, including the outcomes of research into MDMA, regulatory decisions, and safety and efficacy uncertainties regarding psychedelic therapy. More risks are detailed in the Company’s annual information form dated November 29, 2023, available on SEDAR at www.sedarplus.ca. Numinus does not commit to updating forward-looking statements unless required by law. Caution is advised when relying on these statements.

View original content: https://www.prnewswire.com/news-releases/numinus-provides-bi-weekly-update-on-annual-filings-302340871.html

SOURCE Numinus Wellness Inc.